Immuneering shares rise as cancer therapy shows promising results in trial

Immuneering

12/09/2024 22:47

** Shares of Immuneering  IMRX.O  rise 46.1% to $2.09 in
extended trade
    ** Drug developer says its experimental cancer therapy in
combination with chemotherapy showed complete or partial
responses in two pancreatic cancer patients in a mid-stage study
    ** Initial data shows the therapy IMM-1-104 has been well
tolerated - IMRX
    ** Up to last close, stock down 80.5% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))